Sinovac Biotech Co., Ltd   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Beijing China (1999)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2005
NCT00356798
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Sinovac Biotech (Chile) SpA | Sinovac Biotech (Colombia) S.A.S. | Sinovac Biotech Co., Ltd | Sinovac Biotech (Hong Kong) Limited | Sinovac (Dalian) Vaccine Technology Co., Ltd. | Sinovac Research and Development Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (20)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (6 trials)

aluminium chloride (1 trial)

aluminum hydroxide (Gaviscon) (1 trial)

attenuated live hepatitis A vaccine (1 trial)

Bivalent group A and C meningococcal vaccine (Menomune-A/C) (2 trials)

covid-19 vaccine (vero cells) (4 trials)

ev71 vaccine (13 trials)

hepatitis a vaccine, inactivated (vaqta) (7 trials)

hepatitis-a virus (inactivated) / hepatitis-b surface antigen (twinrix) (1 trial)

hepatitis b vaccine (recombinant) (Recombivax) (3 trials)

inactivated covid-19 vaccine (10 trials)

inactivated influenza vaccine (21 trials)

Inactivated polio virus - Enhanced (IPOL) (2 trials)

inactivated sabin strain polio virus (3 trials)

inactivated SARS-Cov-2 vaccine (9 trials)

live attenuated varicella vaccine (Varivax) (9 trials)

measles, mumps, and rubella vaccine (MMR) (2 trials)

methylprednisolone (medrol) (1 trial)

split virion influenza vaccine (4 trials)

vasopressin (vasostrict) (1 trial)

Drugs in Phase 3 Trials (7)

bivalent oral polio vaccine (bopv), type 1 and type 3 (BOPV) (2 trials)

coronavac (1 trial)

live attenuated mumps vaccine (Jeryl Lynn strain) (2 trials)

live oral poliovirus type 1, 2 and 3 (Trivalent oral polio vaccine - Sabin) (1 trial)

omicron covid-19 vaccine (vero cell), inactivated (1 trial)

polio, inactivated poliovirus vaccine (Salk Vaccine) (1 trial)

trivalent covid-19 vaccine (vero cell), inactivated, prototype strain, delta strain and omicron strain (1 trial)

Drugs in Phase 1 Trials (1)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Chickenpox (Phase 3)

Enterovirus Infections (Phase 1)

Foot-and-Mouth Disease (Phase 4)

Hand, Foot and Mouth Disease (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Herpes Zoster (Phase 3)

Infections (Phase 3)

Influenza, Human (Phase 4)

Mouth Diseases (Phase 4)

Mumps (Phase 4)

Pneumococcal Infections (Phase 3)

Poliomyelitis (Phase 3)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 91
  • # of Trial APIs: 28